Tuesday, July 16, 2013 2:58:16 PM
http://www.militaryaerospace.com/articles/2013/03/Mathiesen-DNA-viewpoint.html
Bob MacDowell from APDN commented on the cost of Signature DNA marking
The cost of SigNature DNA marking quoted to Lansdale, and all low-volume OCM's or distributors who will use a third party to apply their DNA mark, is $49,000. For low-volume OCM's and distributors who choose to DNA mark in-house, the cost of the program is $55,000. This includes 35k for creation of one SigNature DNA mark, 1375.00 for equipment, 6,000 for ink, 5k for training, and 2k for QC Report generation. Take off the training and equipment for DNA markers who choose to have a approved Test Lab DNA mark for them.
If DLA reimburses approximately 50 suppliers the cost will roughly be 2.5 to 2.75 million. However, the cost of rework charges due to just one counterfeit component can cost this exact amount. From the Senate Arms Hearings quote "In September 2010, the Missile Defense Agency learned that mission computers for THAAD missiles contained suspect counterfeit memory devices. According to MDA, if the devices had failed, the THAAD missile itself would likely have failed. The cost to fix the problem was nearly $2.7 million."
What is the total cost of rework charges for all the suspect, fraudulent, counterfeit components in missile defense systems, satellites, missile heads, aircraft, etc... The number is well into the hundreds of millions. And who has and will continue to pay these rework charges? Unfortunately, the taxpayer.
Some other quotes from the Senate Arms Hearings:
"The SIA (Semiconductor Industry Association) estimates that counterfeiting costs U.S. semiconductor manufacturers $7.5 billion a year in lost revenue and costs U.S. workers nearly 11,000 jobs."
"Looking at just a slice of the defense contracting universe, committee staff asked a number of large defense contractors and some of their testing companies to identify cases in which they had found suspected counterfeit parts over a 2-year period. They reported 1,800 cases covering a total of 1 million individual parts."
-Bob MacDowell direct dial - 631-444-1090; bob.macdowell@adnas.com
Recent APDN News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/04/2024 10:18:33 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 09:25:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/12/2024 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:05:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/08/2024 09:01:31 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:05:28 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:24:06 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 10:16:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:00:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:05:23 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/07/2023 09:01:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 09:05:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 10:09:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2023 10:02:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:05:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:01:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 08:02:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 09:04:44 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM